


The EU Council Recommendation on AMR:

What are the key takeaways and what will change for healthcare systems?

By 2050, AMR will take an even more significant toll on humanity.¹

More people are expected to die of **AMR** than of cholera, diabetes, measles, and tetanus combined, exceeding deaths caused by cancer.¹

The increasing incidence of antimicrobial resistance in Europe is one of the biggest microbiological problems facing the EU. The epidemiological data and their social and economic impact are worrying.



According to the European Centre for Disease Prevention and Control (ECDC), AMR is Responsible for a Yearly Estimate of²



33,000
deaths solely
within Europe



€1.5 billion
costs to the
EU Economy³



670,000
infections with antimicrobial-
resistant bacteria



1/3
bacteria associated
with hospital-acquired
infections (HAI) are
resistant to antibiotics²

What Are the EU AMR Council Recommendations?

The European Union decided to adopt EU AMR Council Recommendations in 2023 to advance all EU countries' efforts in monitoring and controlling AMR. All countries will be asked to review and update their One Health National Action Plans (NAPs). Future countries' NAPs will focus on measures to avoid and manage hospital outbreaks, which may include⁴:

- Strengthening the Hospital Infection Prevention Control programs, with the use of rapid molecular tests.
- Screening guidelines targeting surveillance and detection of carbapenemase-producing organisms.
- National-level register of carbapenem-resistant infections.

What Are the EU Targets to Tackle AMR?

Health providers will be strongly advised to take appropriate measures to ensure that by 2030⁴:



Reduce by 15%

the total incidence of bloodstream infections with **MRSA**.*



Reduce by 10%

the total incidence of bloodstream infections with third-generation cephalosporins-resistant **Escherichia coli**.*



Reduce by 5%

the total incidence of bloodstream infections with carbapenem-resistant **Klebsiella pneumoniae**.*



Reduce by 20%

the total consumption of **antibiotics** in humans.*

How Can Cepheid Help to Control AMR?

Rapid and accurate diagnosis of carriers is key for the control of AMR, preventing the spread of resistance, and reducing the number of infections. Cepheid is a leader in fast, accurate and easy-to-use AMR diagnostics.



Xpert® Carba-R

Detection and differentiation of KPC, NDM, VIM, IMP-1, and OXA-48 in less than 50 minutes.



Xpert® MRSA NxG

Detection of MRSA directly from nasal swabs in patients at risk for nasal colonization.



Xpert® vanA/vanB

Detection of vancomycin-resistant (*vanA-vanB*) genes in less than 50 minutes.



Xpert® Xpress CoV-2/Flu/RSV plus

Detection and differentiation of SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV).



Scan this QR code to get more information

References:

- 1 O'Neil J. Review on Antimicrobial Resistance. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. May 2016. Accessed November 2023. https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf
- 2 The ECDC/WHO jointly report on Antimicrobial Resistance surveillance in Europe. Accessed November 2023. <https://www.ecdc.europa.eu/sites/default/files/documents/Joint-WHO-ECDC-AMR-report-2022.pdf>
- 3 EMA guidance supports development of new antibiotics. Accessed May 2022. <https://www.ema.europa.eu/en/news/ema-guidance-supports-development-new-antibiotics>
- 4 The Council of the European Union. COUNCIL RECOMMENDATION on stepping up EU actions to combat antimicrobial resistance in a One Health approach. Accessed November 2023. [https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32023H0622\(01\)](https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32023H0622(01))

* Compared to the baseline year 2019.

CE-IVD. In Vitro Diagnostic Medical Device. May not be available in all countries.

CORPORATE HEADQUARTERS

904 Caribbean Drive
Sunnyvale, CA 94089 USA

TOLL FREE +1.888.336.2743
PHONE +1.408.541.4191
FAX +1.408.541.4192

EUROPEAN HEADQUARTERS

Vira Soleth
81470 Maurens-Scopont France

PHONE +33.563.82.53.00
FAX +33.563.82.53.01
EMAIL cepheid@cepheideurope.fr

www.Cepheidinternational.com

© 2024 Cepheid.

3346-01

